Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Shares Drop 5.5 Percent After Analyst Downgrades Stock on Poor Q4 Earnings

This is a corrected version of a previous  article, which mistakenly reported a downgrade by two analysts.

 

NEW YORK, Feb. 24 (GenomeWeb News) - Shares in Third Wave Technologies were down 5.5 percent, or $.40, at $6.82 in late-afternoon trading after Cairns & Company downgraded Third Wave to "Average" from "Above Average"  after the company reported lackluster fourth-quarter revenues.

 

As GenomeWeb News reported yesterday, Third Wave reported a 16.5-percent drop in revenues and almost tripled losses for the fourth quarter of 2004.

 

Total receipts for the three-month period ended Dec. 31, 2004, fell to $8.1 million from $9.7 million during the same quarter in 2003. Third Wave said that more than half, or $4.7 million, of total revenues were derived from clinical molecular diagnostics, meaning that this business segment grew almost 90 percent compared to the fourth quarter of 2003.

 

R&D costs decreased to $2.9 million from $3.8 million during the same period a year ago.

 

Third Wave's net loss for the quarter swelled to $4.7 million, or $.12 per share, from $1.6 million, or $.04 per share, during the last quarter of 2003. This loss was primarily due to severance-related charges, non-recurring litigation, and Sarbanes-Oxley compliance expenses, according to the company.

 

The company said it plans to grow its USclinical molecular diagnostic revenues further in 2005. Third Wave is also finalizing plans for a multi-year agreement with private and government entities in Japanto perform extensive disease association studies. Though details of the study may not be available until early summer, the company anticipates deriving $10 million to $15 million in research product revenue from the project.

 

As of Dec. 31, Third Wave had $66.7 million in cash, cash equivalents, and short-term investments.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.